SCHEMBL6844944

SCHEMBL6844944

COc1ccc(COc2cc(-c3nc(C)cs3)nc3c(Cl)c(O)ccc23)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.37
KDM4E B2RXH2 8/20 0.37
POLB P06746 3/20 0.37
ATM Q13315 1/20 0.37
ALDH1A1 P00352 6/20 0.37
HPGD P15428 5/20 0.37
LMNA P02545 5/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
GAA P10253 2/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
HIF1A Q16665 1/20 0.36
CYP19A1 P11511 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL313106 0.90 MAPT (0.38) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL6844946 0.77 PDE10A (0.39) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL313767 0.74 MAPT (0.39) MAPTKDM4EPOLBALDH1A1LMNA
SCHEMBL10271218 0.72 PDE10A (0.34) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL8135887 0.71 PDE10A (0.34) MAPTPOLBSMN1; SMN2NPC1RAB9A
SCHEMBL314529 0.70 KDM4E (0.38) MAPTKDM4EPOLBATMALDH1A1
SCHEMBL13637183 0.70 MAPT (0.42) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL312965 0.69 CSF1R (0.43) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL3625504 0.69 MAPT (0.40) MAPTKDM4EPOLBALDH1A1HPGD
SCHEMBL13090548 0.69 MAPT (0.40) MAPTKDM4EPOLBALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011017389-A1 MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV IDENIX PHARMACEUTICALS, INC. (US) 2011-02-10 WO disclosed